Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 438Triple Negative Breast Neoplasms 50Neoplasm Metastasis 24Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 22Colorectal Neoplasms 18Carcinoma, Intraductal, Noninfiltrating 18Neoplasms 16Pancreatic Neoplasms 14Prostatic Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 12Colonic Neoplasms 11Breast Neoplasms, Male 10Urinary Bladder Neoplasms 8Small Cell Lung Carcinoma 8Melanoma 8Fatigue 8Breast Carcinoma In Situ 8Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lymphedema 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Breast Cancer Female 6Testicular Neoplasms 5Pain 5Esophageal Neoplasms 5

Interventions

Vortioxetine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Unipolar Major Depression × Breast × Clear all
NCT02637466 2016-09-30

Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers

University of Miami

Phase 4 Withdrawn
Breast

Unipolar Major Depression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡